Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2
Samo za registrovane korisnike
2020
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
The Bacillus Calmette–Guerin vaccine is still widely used in the developing world. The vaccination prevents infant death not only from tuberculosis but also from unrelated infectious agents, especially respiratory tract infections and neonatal sepsis. It is proposed that these off-target protective effects of the BCG vaccine are mediated by the general long-term boosting of innate immune mechanisms, also termed “trained innate immunity”. Recent studies indicate that both COVID-19 incidence and total deaths are strongly associated with the presence or absence of national mandatory BCG vaccination programs and encourage the initiation of several clinical studies with the expectation that revaccination with BCG could reduce the incidence and severity of COVID-19. Here, presented results from the bioinformatics analysis of the Mycobacterium bovis (strain BCG/Pasteur 1173P2) proteome suggests four immunodominant antigens that could induce an immune response against SARS-CoV-2.
Ključne reči:
SARS-CoV-2 / COVID-19 / BCG / vaccine / clinical studyIzvor:
Journal of Proteome Research, 2020, 19, 11, 4649-4654Finansiranje / projekti:
- Ministry of Education, Science and Technological Development of the Republic of Serbia
DOI: 10.1021/acs.jproteome.0c00410
ISSN: 1535-3893
PubMed: 32794723
WoS: 000589944200037
Scopus: 2-s2.0-85095861082
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Glišić, Sanja AU - Perović, Vladimir R. AU - Senćanski, Milan V. AU - Paessler, Slobodan AU - Veljković, Veljko PY - 2020 UR - https://vinar.vin.bg.ac.rs/handle/123456789/9723 AB - The Bacillus Calmette–Guerin vaccine is still widely used in the developing world. The vaccination prevents infant death not only from tuberculosis but also from unrelated infectious agents, especially respiratory tract infections and neonatal sepsis. It is proposed that these off-target protective effects of the BCG vaccine are mediated by the general long-term boosting of innate immune mechanisms, also termed “trained innate immunity”. Recent studies indicate that both COVID-19 incidence and total deaths are strongly associated with the presence or absence of national mandatory BCG vaccination programs and encourage the initiation of several clinical studies with the expectation that revaccination with BCG could reduce the incidence and severity of COVID-19. Here, presented results from the bioinformatics analysis of the Mycobacterium bovis (strain BCG/Pasteur 1173P2) proteome suggests four immunodominant antigens that could induce an immune response against SARS-CoV-2. T2 - Journal of Proteome Research T2 - Journal of Proteome ResearchJ. Proteome Res. T1 - Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2 VL - 19 IS - 11 SP - 4649 EP - 4654 DO - 10.1021/acs.jproteome.0c00410 ER -
@article{ author = "Glišić, Sanja and Perović, Vladimir R. and Senćanski, Milan V. and Paessler, Slobodan and Veljković, Veljko", year = "2020", abstract = "The Bacillus Calmette–Guerin vaccine is still widely used in the developing world. The vaccination prevents infant death not only from tuberculosis but also from unrelated infectious agents, especially respiratory tract infections and neonatal sepsis. It is proposed that these off-target protective effects of the BCG vaccine are mediated by the general long-term boosting of innate immune mechanisms, also termed “trained innate immunity”. Recent studies indicate that both COVID-19 incidence and total deaths are strongly associated with the presence or absence of national mandatory BCG vaccination programs and encourage the initiation of several clinical studies with the expectation that revaccination with BCG could reduce the incidence and severity of COVID-19. Here, presented results from the bioinformatics analysis of the Mycobacterium bovis (strain BCG/Pasteur 1173P2) proteome suggests four immunodominant antigens that could induce an immune response against SARS-CoV-2.", journal = "Journal of Proteome Research, Journal of Proteome ResearchJ. Proteome Res.", title = "Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2", volume = "19", number = "11", pages = "4649-4654", doi = "10.1021/acs.jproteome.0c00410" }
Glišić, S., Perović, V. R., Senćanski, M. V., Paessler, S.,& Veljković, V.. (2020). Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2. in Journal of Proteome Research, 19(11), 4649-4654. https://doi.org/10.1021/acs.jproteome.0c00410
Glišić S, Perović VR, Senćanski MV, Paessler S, Veljković V. Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2. in Journal of Proteome Research. 2020;19(11):4649-4654. doi:10.1021/acs.jproteome.0c00410 .
Glišić, Sanja, Perović, Vladimir R., Senćanski, Milan V., Paessler, Slobodan, Veljković, Veljko, "Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2" in Journal of Proteome Research, 19, no. 11 (2020):4649-4654, https://doi.org/10.1021/acs.jproteome.0c00410 . .